NCT07422987 GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
| NCT ID | NCT07422987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Kansas Medical Center |
| Condition | Body Composition |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-02-12 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-02-12 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
Eligibility Criteria
Inclusion Criteria: * Females * Age 35-60 year * BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS) * Newly prescribed a GLP-1RA medication * English speaking * Body weight stable for the past 6 months Exclusion Criteria: * Pregnant women * Under age 35 or over age 60 * Born male * Cannot consent for themselves * Cannot read and speak in English * Type 2 diabetes * Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing) * Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation) * Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)
Contact & Investigator
Johanna Finkle, MD
PRINCIPAL INVESTIGATOR
University of Kansas Medical Center
Frequently Asked Questions
Who can join the NCT07422987 clinical trial?
This trial is open to female participants only, aged 35 Years or older, up to 60 Years, studying Body Composition. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07422987 currently recruiting?
Yes, NCT07422987 is actively recruiting participants. Contact the research team at jfinkle2@kumc.edu for enrollment information.
Where is the NCT07422987 trial being conducted?
This trial is being conducted at Kansas City, United States.
Who is sponsoring the NCT07422987 clinical trial?
NCT07422987 is sponsored by University of Kansas Medical Center. The principal investigator is Johanna Finkle, MD at University of Kansas Medical Center. The trial plans to enroll 50 participants.